What SiHC does for your launch
Senior, hands-on support for small and mid-sized companies bringing a new product to market, and for larger companies that need extra launch capacity.
Launch readiness
A clear plan from approval to first patient: what has to be in place, who owns it, and when. Gaps are found early, while there is still time to close them.
- readiness assessment
- launch plan
- cross-functional set-up
Commercial & launch strategy
Positioning, target customers and the commercial model that fits your product and your market, whether you build your own team or work with a partner.
- positioning
- go-to-market model
- KAM & field strategy
Business development
Finding and shaping the partnerships that take a product further: licensing, distribution and co-promotion, from first conversation to working agreement.
- partner search
- in- & out-licensing
- deal support
Market access & regional partnering
Entering Benelux and wider Europe from Australia and New Zealand, or Oceania from Europe. Local market insight, access requirements and the right partners on each side.
- Benelux entry
- Oceania entry
- access & pricing input
A method, not a lucky break
Six assignments in four years, each run with the same structured approach. One example:
A novel lung cancer therapy, launched in nine months
A company preparing its first launch in a new market needed its organisation, processes and customer engagement ready on day one. The full launch was prepared in a third of the usual runway.
Launches across therapy areas and company sizes
From global originators to mid-sized specialty companies, with launches spanning originator and biosimilar biologics and advanced therapies.
- OncologyAnti-PD-1 therapy in lung cancer, cervical cancer and basal cell carcinoma, for a global company
- NeurologyAnti-CD20 antibody in multiple sclerosis, for a mid-sized European company
- OncologySubcutaneous breast cancer treatment, relaunch for a global company
- DermatologyTherapy with a new mechanism of action, for a mid-sized company
- ImmunologyFirst-in-class originator receptor therapy
- ImmunologyMultiple biosimilar antibodies and receptors
- OncologyOncolytic virus therapy for in-transit metastases
A bridge that works in both directions
For Australian and New Zealand companies
Practical insight into European markets: where the opportunities are, which regulatory and commercial hurdles to expect, and who to partner with in Benelux and beyond.
For European companies
A route into Oceania through an active network in the Australian biotech and medtech community, and first-hand knowledge of what is happening there.
Planning a launch, or curious about the other side of the world?
Send a short message to discuss a launch or a partnership. Or join the mailing list for occasional updates on biotech and medtech markets in Europe and Oceania.